Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, USA.
J Biol Chem. 2011 Jul 8;286(27):24451-7. doi: 10.1074/jbc.M111.238758. Epub 2011 May 23.
Human and porcine coagulation factor VIII (fVIII) display a biosynthetic efficiency differential that is being exploited for the development of new protein and gene transfer-based therapies for hemophilia A. The cellular and/or molecular mechanism(s) responsible for this phenomenon have yet to be uncovered, although it has been temporally localized to post-translational biosynthetic steps. The unfolded protein response (UPR) is a cellular adaptation to structurally distinct (e.g. misfolded) or excess protein in the endoplasmic reticulum and is known to be induced by heterologous expression of recombinant human fVIII. Therefore, it is plausible that the biosynthetic differential between human and porcine fVIII results from differential UPR activation. In the current study, UPR induction was examined in the context of ongoing fVIII expression. UPR activation was greater during human fVIII expression when compared with porcine fVIII expression as determined by ER response element (ERSE)-luciferase reporter activity, X-box-binding protein 1 (XBP1) splicing, and immunoglobulin-binding protein (BiP) up-regulation. Immunofluorescence microscopy of fVIII expressing cells revealed that human fVIII was notably absent in the Golgi apparatus, confirming that endoplasmic reticulum to Golgi transport is rate-limiting. In contrast, a significant proportion of porcine fVIII was localized to the Golgi indicating efficient transit through the secretory pathway. Overexpression of BiP, an integral UPR protein, reduced the secretion of human fVIII by 50%, but had no effect on porcine fVIII biosynthesis. In contrast, expression of BiP shRNA increased human fVIII expression levels. The current data support the model of differential engagement of UPR by human and porcine fVIII as a non-traditional mechanism for regulation of gene product biosynthesis.
人和猪凝血因子 VIII(fVIII)显示出生物合成效率的差异,这一差异正被用于开发新型蛋白质和基因转移治疗血友病 A 的方法。尽管该现象已被暂时定位到翻译后生物合成步骤,但负责这一现象的细胞和/或分子机制尚未被揭示。未折叠蛋白反应(UPR)是细胞对内质网中结构不同(例如错误折叠)或过量蛋白的适应机制,已知其会被重组人 fVIII 的异源表达所诱导。因此,推测人 fVIII 和猪 fVIII 之间的生物合成差异是由于 UPR 激活的差异所致。在本研究中,在持续表达 fVIII 的背景下研究了 UPR 的诱导。通过 ER 反应元件(ERSE)-荧光素酶报告活性、X 框结合蛋白 1(XBP1)剪接和免疫球蛋白结合蛋白(BiP)的上调,发现人 fVIII 表达时 UPR 的激活比猪 fVIII 表达时更大。表达 fVIII 的细胞的免疫荧光显微镜检查显示,人 fVIII 在高尔基器中明显缺失,这证实了内质网到高尔基体的运输是限速的。相比之下,相当一部分猪 fVIII 被定位到高尔基,表明其穿过分泌途径的效率很高。BiP 的过表达(一种完整的 UPR 蛋白)将人 fVIII 的分泌减少了 50%,但对猪 fVIII 的生物合成没有影响。相反,BiP shRNA 的表达增加了人 fVIII 的表达水平。目前的数据支持人 fVIII 和猪 fVIII 通过 UPR 进行差异结合的模型,这是调节基因产物生物合成的一种非传统机制。